Customs Duty Scrapped on 17 Cancer Drugs

  



Union Finance Minister Nirmala Sitharaman has announced major relief for patients battling cancer and rare diseases in the Union Budget 2026. The Budget removes basic customs duty on 17 cancer-related drugs and extends duty exemptions to treatments for seven rare diseases, aiming to reduce the financial burden of life-saving therapies that are largely dependent on imports.

Relief for Cancer Patients Through Duty Exemption

Presenting the Budget in Parliament, Sitharaman said the removal of basic customs duty on 17 cancer drugs is intended to make advanced and complex treatments more affordable. Imported oncology medicines currently attract customs duty, which significantly inflates retail prices. By eliminating this levy, the government expects a direct reduction in treatment costs across several high-value cancer therapies, improving access for patients across income groups.

Impact on Treatment Costs and Access

Health experts have noted that imported medicines form a substantial portion of overall cancer treatment expenses in India. Even marginal reductions in drug prices can translate into meaningful savings over prolonged treatment cycles. The duty exemption is therefore expected to reduce out-of-pocket expenditure, particularly for patients without comprehensive health insurance, and help prevent catastrophic healthcare spending among vulnerable households.

Extended Relief for Rare Diseases

Beyond oncology drugs, the Budget extends customs duty relief to medicines and specialised foods used in the treatment of seven additional rare diseases. Under the proposal, personal imports of such drugs and medical nutrition products will be exempt from import duties. This measure benefits patients who rely on personalised or niche therapies that are not manufactured domestically due to limited demand and high production costs.

#CancerResearch #Oncology #CancerBiology #TumorMicroenvironment #CancerAwareness #PrecisionMedicine #CancerTherapy #MolecularOncology #TranslationalResearch #BiomedicalScience

World Cell Biologist Awards: 

Website Link : cellbiologist.or

Follow Us On : 
Tumblr ; tumblr.ccom/

Comments

Post a Comment

Popular posts from this blog

Uttrakhand Forest Department Establishes Mahabharata Vatika

Image
  The Uttarakhand Forest Department has established two gardens in Haldwani, showcasing plant species referenced in ancient Indian epics. These gardens, named Ramayana Vatika and Mahabharata Vatika, aim to highlight the ecological wisdom embedded in these texts. Mahabharata Vatika Overview Mahabharata Vatika spans one acre and features 37 plant species mentioned in the epic. Chief Conservator of Forests Sanjeev Chaturvedi emphasised the research behind selecting these species. The garden features important plant species such as: Ecological Significance The garden puts stress on the importance of forests as depicted in the Mahabharata. It references the Vana Parva, which discusses tree planting and wildlife conservation . The epic highlights the mutual dependence of tigers and forests, a concept vital to contemporary conservation efforts. Cultural Connections Chaturvedi brought into light that the Mahabharata teaches the spiritual significance of planting trees. He mentioned Bhish...
Read more

CAR T-Cell Therapy for Cancer

Image
  India has recently made strides in cancer treatment with the introduction of CAR T-cell therapy . The results from the first clinical trials have been published in The Lancet, showcasing a remarkable success rate. This therapy is a game changer for patients with blood cancers. It offers hope to those who have exhausted other treatment options. What is CAR T-Cell Therapy? CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is an innovative treatment that harnesses the body’s immune system. It trains T-cells to target and destroy cancer cells. This therapy is specifically designed for certain blood cancers. It is particularly beneficial for patients whose cancer has relapsed or failed to respond to standard treatments. Clinical Trial The clinical trials reported a response rate of nearly 73%. This indicates that number of patients benefited from the treatment. The trials also provided critical data on survival rates for patients with acute lymphoblastic leukaemia and l...
Read more

What is Zolgensma?

Image
  Spinal Muscular Atrophy (SMA) is a rare genetic disease affecting muscle function. In India, treatment options are limited, mainly due to high costs. The gene therapy drug, Zolgensma , costs around 16 crore rupees. Despite this, some families are finding ways to access treatment. About Spinal Muscular Atrophy (SMA) SMA is a genetic disorder that leads to the loss of motor neurons in the spinal cord. This results in muscle weakness and atrophy. Symptoms often appear in infancy. Children may struggle with basic movements like lifting their heads or crawling. Early diagnosis is crucial for effective treatment. About Zolgensma Zolgensma (onasemnogene abeparvovec-xioi) is a revolutionary gene therapy for SMA. It addresses the root cause by replacing the missing or defective SMN1 gene . This therapy can improve motor function in affected children. Although it is costly, it represents hope for many families. SMA is not as rare as once thought. The global prevalence is estimated at 1 in ...
Read more